Microsecond molecular dynamics simulations revealed the inhibitory potency of amiloride analogs against SARS–CoV–2 E viroporin

Abdullah All Jaber¹, Zeshan Mahmud Chowdhury¹,², Arittra Bhattacharjee¹,², Muntahi Mourin³, Chaman Ara Keya¹, Zaied Ahmed Bhuyan¹*

¹Department of Biochemistry and Microbiology, North South University, Bashundhara, Dhaka-1229, Bangladesh
²Bioinformatics Division, National Institute of Biotechnology, Ganakbari, Ashulia, Savar, Dhaka-1349, Bangladesh
³Department of Microbiology, University of Manitoba, 66 Chancellors Cir, Winnipeg, MB R3T 2N2, Canada

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV–2) encodes small envelope protein (E) that plays a major role in viral assembly, release, pathogenesis, and host inflammation. Previous studies demonstrated that pyrazine ring containing amiloride analogs inhibit this protein in different types of coronavirus including SARS-CoV–1 small envelope protein E (SARS-CoV–1 E). SARS-CoV–1 E has 93.42% sequence identity with SARS-CoV–2 E and shared a conserved domain NS3/small envelope protein (NS3_envE). Amiloride analog hexamethylene amiloride (HMA) can inhibit SARS-CoV–1 E. Therefore, we performed molecular docking and dynamics simulations to explore whether amiloride analogs are effective in inhibiting SARS-CoV–2 E. To do so, SARS-CoV–1 E and SARS-CoV–2 E proteins were taken as receptors while HMA and 3-amino-5-(azepan-1-yl)-N-(diaminomethylidene)-6-pyrimidin-5-ylpyrazine-2-carboxamide (3A5NP2C) were selected as ligands. Molecular docking simulation showed higher binding affinity scores of HMA and 3A5NP2C for SARS-CoV–2 E than SARS-CoV–1 E. Moreover, HMA and 3A5NP2C engaged more amino acids in SARS-CoV–2 E. Molecular dynamics simulation for 1 μs (1,000 ns) revealed that these ligands could alter the native structure of the proteins and their flexibility. Our study suggests that suitable amiloride analogs might yield a prospective drug against coronavirus disease 2019.

Keywords: COVID-19, hexamethylene amiloride, SARS-CoV–2 E, virology, viroporin

Introduction

Severe acute respiratory syndrome coronavirus–2 (SARS-CoV–2), the etiologial agent of coronavirus disease 2019 (COVID–19), is a threat to the global public health and economy [1]. SARS-CoV or SARS-CoV–1, which is around 80% genetically similar to SARS-CoV–2, initiated the fatal outbreak of severe acute respiratory syndrome (SARS) in Southeast China, 2002 [2–5]. SARS-CoV–1 and SARS-CoV–2 encode viroporins (VPs) that exhibit ion channel (IC) activity in both host cell and virion. VPs are crucial factors for viral pathogenesis, infection cycle, virion morphogenesis, assembly, and viral release from the...
host cells [6,7]. Besides SARS-like coronaviruses, other pathogenic human viruses such as human immunodeficiency virus-1 (HIV-1), influenza A virus (IAV), rotavirus also encode VPs [7-10]. VPs induce ion imbalance within host cells and disrupt cellular pathways via various protein-protein interactions [11].

SARS-CoV-1 encodes VPs from small envelope protein E, ORF3a and ORF8a genes. Protein E and ORF3a interact with cellular proteins via PDZ-binding motif and exerts IC activity. These functions are essential for optimal viral replication. However, among these 3 VP-forming genes, protein E was indispensable for viral virulence [12]. Protein E forms calcium ion (Ca$^{2+}$) channels in the endoplasmic reticulum golgi apparatus intermediate compartment (ER-GIC)/Golgi membranes. These ICs alter calcium homeostasis in host cells and activate the cytosolic innate immune signaling receptor NLR family pyrin domain containing 3 inflammasome [13,14]. Absence of protein E attenuates the viral infectious activity by reducing nuclear factor kB mediated inflammation [15]. Therefore, protein E can be a plausible therapeutic target for COVID-19.

Previous studies demonstrated that VP-like prototypic M2 proton selective channel of IAV can be an ideal target for antiviral development [16]. All coronavirus E proteins are assumed to form cation-selective ion channels which participate in viral replication and virus's life cycle [17,18]. The actions of VPs in SARS-CoV-2 may also be figured out from other CoVs e.g., Middle East respiratory syndrome coronavirus and human coronavirus 229E (HCoV-229E) [5,6,19]. Deletion of E gene from SARS-CoV-1 significantly decreased the viral pathogenesis [15]. Moreover, the usage of the channel blocking compounds such as amiloride analogs had substantially alleviated the viral replications of HCoV-229E, murine hepatitis virus (MHV), and SARS-CoV-1 [20,21]. Here, the amiloride analogs interacted with the E proteins and inhibited the functions of VP [22,23]. These results have raised a possibility to develop a broad spectrum antiviral drug against coronaviruses [20-23]. Aside from coronaviruses, Amiloride derivatives (particularly hexamethylene amiloride [HMA]) were found to be efficient inhibitors of ICs in hepatitis C virus, influenza virus, and HIV-1 [7-9]. Since E gene of SARS-CoV-1 and SARS-CoV-2 are highly identical (Table 1, Supplementary Data 1), implementation of different in silico tools can unveil the anti-SARS-CoV-2 E mechanisms of amiloride analogs [24,25].

Amiloride is a pyrazine ring containing compound that inhibits sodium-hydrogen antipporter 1 (NHE-1) and promotes diuresis [26]. Analogs of amiloride such as S-(N,N-Hexamethylene) amiloride or HMA (PubChem CID: 1794) can inhibit urokinase-type plasminogen activator (uPA) which is an important protease for tumor cell to undergo metastasis [27,28]. HMA has antiviral activities with little K$^+$ sparing diuretic effect and 3-Amino-5-(azepan-1-yl)-N-(diaminomethylidene)-6-pyrimidin-5-ylpyrazine-2-carboxamide (3ASNP2C) (PubChem CID: 137348787), a structurally similar compound, has very little cytotoxic properties in human cells [27,29]. In this study, we explored the anti-SARS-CoV-2 E activities of HMA and 3ASNP2C. Through molecular docking and molecular dynamics simulations, we showed that these small molecules could bind and alter the structure of SARS-CoV-2 E in golgi membrane lipid bilayer. Our study suggests that amiloride analogs could be a druggable compound for COVID-19.

**Methods**

**Characterization of SARS-CoV-2 E VP**

For characterization of the SARS-CoV-2 E, the E protein (accession: YP_009724392.1) went under Protein Basic Local Alignment Search Tool (BLASTp) in National Center for Biotechnology Information (NCBI) database. To find homologous sequences in other CoVs, SARS-CoV-2 was excluded during this BLASTp. Top 4 hits in Supplemental Data 1 were taken for characterization. Afterward, E protein of SARS-CoV-1 GD01 (accession: AAP51230.1) was also included. The protein sequences were uploaded in ProtParam, Pfam, and

| Serial No. | Virus                                    | NCBI accession No. for E protein | No. of AA’s | Outside | Inside | Theoretical pl | Instability Index | Aliphatic Index | GRAVY |
|------------|------------------------------------------|----------------------------------|------------|---------|--------|---------------|------------------|-----------------|-------|
| 1          | Bat SARS-like coronavirus                 | AVP78033.1                       | 75         | 1-11   | 35-75  | 8.57          | 38.68            | 144              | 1.128 |
| 2          | SARS-related coronavirus                  | AP040581.1                       | 76         | 1-11   | 35-76  | 7.69          | 35.26            | 144              | 1.129 |
| 3          | Coronavirus BtRl-BetaCoV/SC2018           | QDF43816.1                       | 76         | 1-11   | 35-76  | 6.01          | 31.47            | 147.24           | 1.145 |
| 4          | Rhinolophus affinis coronavirus           | AOX37560.1                       | 76         | 1-11   | 35-76  | 6.01          | 33.02            | 145.92           | 1.176 |
| 5          | SARS-CoV-2                                | YP_009724392.1                   | 75         | 1-11   | 35-76  | 8.57          | 38.68            | 144              | 1.128 |
| 6          | SARS coronavirus GD01                     | AAP51230.1                       | 76         | 1-11   | 35-75  | 6.01          | 30.48            | 142.11           | 1.111 |
| Average    |                                         | -                                | 75.67      | -      | -      | 7.12          | 33.782           | 144.67           | 1.14  |

GRAVY, grand average of hydropathicity; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
THMM to analyze their physicochemical properties, domains, and transmembrane helices [30-32]. Their phylogenetic characterization was conducted by CLC Drug Discovery Workbench 3.0 using default parameters (https://digitalinsights.qiagen.com).

Three-dimensional structure generations of E proteins
E proteins of SARS-CoV-1 and SARS-CoV-2 were generated via Rosetta (https://rosetta.bakerlab.org) [33]. The structures were refined with three-dimensional refine and Galaxy Refine [34,35]. The qualities of the generated structures were assessed using SWISS structure assessment [36].

Pharmacokinetic property exploration of the ligands and preparation for molecular docking
The molecules were selected after going through literature [27,28]. The canonical smiles of 5-(N,N-hexamethylene) amiloride or HMA and 3ASNP2C were uploaded in SWISS-ADME for exploring the pharmacokinetic properties (absorption, distribution, metabolism, excretion) [37]. The canonical SMILES (Simplified molecular-input line-entry system) were collected from PubChem database and transferred into protein data bank file via Online SMILES Translator and Structure File Generator (https://cactus.nci.nih.gov/translate/) [38].

Molecular docking and dynamic simulations
The selected ligands went under blind molecular docking simulation against SARS-CoV-1 and SARS-CoV-2 E proteins via AutoDock tools 1.5.6 [39]. The ligand-receptor interactions between drug-receptor complexes were visualized by BIOVIA Discovery Studio (http://www.discover.3ds.com) and PyMOL Molecular Graphics System, Version 2.3.3 Schrödinger, LLC [40] and UCSF Chimera [41]. The dynamics and stability of SARS-CoV-1 and SARS-CoV-2 E proteins with amiloride analogs bound complexes were compared by carrying out MD simulations. For MD simulations, the drug-bound complexes were embedded in a lipid bilayer membrane composed of 36% phosphatidylcholine, 21% phosphatidyethanolamine, 21% cholesterol, 6% phosphatidylserine. This lipid bilayer mimics the lipid composition of golgi complex [42]. The SARS-CoV-1 VPs generally target golgi apparatus [43]. The total system consisted of about 120,000 atoms in an orthorhombic simulation cell with a free KCl concentration of 150 mM. Equilibrium MD simulations were performed after energy minimization and 1,000 ns of equilibration with position restraints. The protein, water, and lipid components were energy minimized using Charrm-Gui Bilayer Builder [44] and Gromacs 2019.2 [45,46]. All simulations were carried out under periodic boundary condi-

tions at constant temperature (T = 310°K) and pressure (P = 1 bar). Then the root mean square deviation (RMSD) and Root Mean Square Fluctuation (RMSF) of C-a carbon from wild type apo-SARS-CoV-1 E and apo-SARS-CoV-2 E with ligand bound complexes were analyzed by g_rms, g_rmsf tools.

Results
SARS-CoV-2 E protein contains relatively higher instability index
According to NCBI BLASTp, SARS-CoV-1 and SARS-CoV-2 E proteins share 93.42% sequence identity. The selected CoV E protein contains nearly same numbers of amino acids outside and inside of the transmembrane. Their grand average of hydropathicity values are not significantly diverse. However, SARS-CoV-2 E has a higher theoretical pl (isoelectric point) and instability index than average value. Only Bat SARS-like coronavirus has this type of properties.

All of the E proteins have Non-structural protein NS3/Small envelope protein E domain (Fig. 1). Some insignificant domains such as Ellis van Crevel protein 2 like protein and FAM163 family were found in SARS-CoV-2 E. This insignificant FAM163 family domain was absent in SARS-CoV-1 E (Supplementary Data 1).

SARS-CoV-2 E protein demonstrated higher binding affinity for the ligands than SARS-CoV-1 E
The E proteins of SARS-CoV-1 and SARS-CoV-2 went under homology modeling and their structures were refined. More than 97% amino acids were in favored region of Ramachandran plot. Details about the structural qualities are given in Supplementary Data 2. To target SARS-CoV-2 E, anticancer amiloride analogs, i.e., HMA and 3ASNP2C were used in this study (Fig. 2). Their physicochemical and pharmacokinetic properties are given in (Table 2) and Supplementary Data 2. They have similar bioavailability.

HMA might inhibit CYP1A2 and CYP2C19. However, this characteristic was absent in 3ASNP2C. SARS-CoV-1 E demonstrated −5.5 kcal/mol and −5.8 kcal/mol binding affinity scores with HMA and 3ASNP2C respectively. Whereas HMA and 3ASNP2C interacted with SARS-CoV-2 E with −7.3 kcal/mol and −7.1 kcal/mol binding affinity scores, respectively (Table 2).

Only Phe 4 of SARS-CoV-1 E interacted with both HMA and 3ASNP2C. Whereas six common residues of SARS-CoV-2 protein E Phe 4, Asn 66, Leu 12, Tyr 57, Val 62, Lys 63 participated in ligand-receptor interactions (Fig. 3). Moreover, HMA and 3ASNP2C interacted via H-bonds with SARS-CoV-2 E which was not observed in SARS-CoV-1 E. The pyrazine ring, which is essential

https://doi.org/10.5808/gi.21040
for the structure activity relationship of amiloride, showed various types of interactions. The extra pyrimidine group of 3A5NP2C engaged more amino acids in the receptors.

HMA and 3A5NP2C altered the wild type E proteins structures

The ligand-receptor complexes went under 1 ms simulation or 1,000 ns MD simulation. The ligand bound and ligand-free E proteins deviated in same pattern for less than 100 ns and after that their RMSD values were different (Fig. 4). Ligand-receptor complexes also showed altered mobility, especially in the cytoplasmic, transmembrane, and non-cytoplasmic regions. SARS-CoV-2-E–3A5NP2C complex also demonstrated different RMSD value at 100ns whereas SARS-CoV-2-E–HMA showed less deviations. On the other hand, HMA reduced more fluctuation than 3A5NP2C in these domains of SARS-CoV-2 E proteins. During the simulation, the RMSD of SARS-CoV-2-E-HMA (green line) did not show equal overlapping value after few seconds. This indicated that the bonded drug altered the wild type conformations hence it could not execute the IC activities [22]. Similar patterns were also observed between SARS-CoV-2 E

Fig. 1. E protein is highly conserved among SARS-CoV-2 and SARS-CoV-1. Only black regions (underlined with green bars) are variable. All of the E proteins have NS3/small envelope protein E domain (NS3 envE). According to the phylogenetic tree, SARS-CoV-2 E protein is mostly closed to bat SARS-like coronavirus E protein. E, envelope; SARS-CoV, severe acute respiratory syndrome coronavirus.

Fig. 2. Selected compound for E protein inhibition. (A) 5-(N,N-hexamethylene) amiloride is a well-known coronavirus viroporin inhibitor. (B) Structurally similar 3-amino-5-(azepan-1-yl)-N-(diaminomethylidene)-6-pyrimidin-5-ylpyrazine-2-carboxamide (3A5NP2C). This small molecule has anticancer activity. E, envelope.
Table 2. Major physiochemical and pharmacokinetic characteristics of the selected anticancer amiloride analogs

| Characteristic                      | 5-(N,N-Hexamethylene) amiloride (HMA) | 3-Amino-5-(azepan-1-yl)-N-(diaminomethylidene)-6-pyrimidin-5-ylpyrazine-2-carboxamide (3A5NP2C) |
|------------------------------------|---------------------------------------|---------------------------------------------------------------------------------------------|
| Molecular weight                   | 311.77                                | 355.4                                                                                       |
| H-bond acceptors                   | 3                                    | 4                                                                                           |
| H-bond donors                      | 4                                    | 6                                                                                           |
| GI absorption                      | High                                  | Low                                                                                         |
| BBB permeant                       | No                                    | No                                                                                          |
| Inhibitory substrate of:           | CYP1A2, CYP2C19                       | No data available                                                                           |
| Bioavailability score              | 0.55                                  | 0.55                                                                                       |
| Binding affinity score (SARS-CoV-1 E) (kcal/mol) | −5.5                       | −5.8                                                                                       |
| Binding affinity score (SARS-CoV-2 E) (kcal/mol) | −7.3                       | −7.1                                                                                       |

GI, gastrointestinal absorption; BBB, blood brain barrier; SARS-CoV, severe acute respiratory syndrome coronavirus; E, envelope protein.

Fig. 3. Interactions between 3A5NP2C with SARS-CoV-1 E (A) and SARS-CoV-2 E (B). 5-(N,N-Hexamethylene) amiloride interactions with SARS-CoV-1 E (C) and SARS-CoV-2 E viroporins (D). 3A5NP2C, 3-amino-5-(azepan-1-yl)-N-(diaminomethylidene)-6-pyrimidin-5-ylpyrazine-2-carboxamide; E, envelope; SARS-CoV, severe acute respiratory syndrome coronavirus.

and drug bound SARS-CoV-2 E. RMSF analysis showed that these compounds reduced the mobility of N and C terminal region of SARS-CoV-2 E (Fig. 4).

The schematic representation of the whole study is given in Fig. 5.

Discussion

VPs are involved in viral assembly and pathogenesis, which promotes ion imbalance within host cells, disrupting cellular pathways [11,43,47]. Therefore, impeding their activity by specific drugs of-
Fig. 4. Molecular dynamics simulation of amiloride analogs and the receptors. The root mean square deviation (RMSD) (A) and root mean square fluctuation (RMSF) (B) of SARS-CoV-1 and 2 E proteins with and without amiloride analogs. SARS-CoV, severe acute respiratory syndrome coronavirus; E, envelope.

Fig. 5. The schematic representation of the whole study. E, envelope; SARS-CoV, severe acute respiratory syndrome coronavirus; ERGIC, Endoplasmic Reticulum Golgi Apparatus Intermediate Compartment.
fiers promising antiviral therapeutics [6,48]. Coronaviruses, including SARS-CoV-1, express small envelope (E) protein that forms VPs. These VPs act as cation-selective ion channels in lipid bilayers that are able to pump Na+ and K+ ions [49]. The transmembrane α-helical domain of E forming multimeric α-helical bundle is responsible for the IC activity [50]. Similar to SARS-CoV-1, SARS-CoV-2 also encodes VP forming E protein [51,52]. This E protein is 93.42% identical with SARS-CoV-1 E. SARS-CoV-2 E has a conserved NS3/Small envelope protein E domain (NS3_envE) that triggers inflammation in host cells (Fig. 1) [13].

Previous reports showed that NHE-1 blocker HMA inhibits HCoV-229E and MHV E protein IC conductance in lipid bilayers [21]. Functions of SARS-CoV-1 E got significantly reduced by HMA in human embryonic kidney 293 cells [22]. Moreover, HMA and 3ASNP2C have anticancer properties [27,28]. According to SWISS-ADME, these molecules are impenetrable through blood brain barrier and can circulate in the body with 0.55 bioavailability score. 3ASNP2C drug compound has lower gastrointestinal absorption than HMA. However, HMA might act as an inhibitory substrate of CYP1A2 and CYP2C19 enzyme. Specific modification in the side chain of amiloride analogs might make the compound a potential broad spectrum anti-microbial compound with safer ADMET properties and efficacy. Hence, further studies may contribute to the structural modification of these analogs devising a safer and more effective antiviral [53].

In this study, we have found that the structural characteristics of HMA and similar compound 3ASNP2C exhibited more binding affinity score with SARS-CoV-2 E than SARS-CoV-1 E. Phe 4 of SARS-CoV-1 E was the common interacted residue for both HMA and 3ASNP2C whereas SARS-CoV-2 E interacted via Phe 4, Asn 66, Leu 12, Tyr 57, Val 62, Lys 63. This indicated that these ligands could bind to both inside (amino acid number: 1–11), outside (amino acid number: 35–75) and within transmembrane helix (amino acid number: 12–34) regions of SARS-CoV-2 E (Table 1).

The E proteins and drug-receptor complexes were placed in a Golgi lipid bilayer model for MD simulations. SARS-CoV-2 E showed higher mobility and deviations in bilayer than SARS-CoV-1 E. Especially the outside N and C terminal regions of the protein were more mobile than SARS-CoV-1 E. Since, SARS-CoV-2 can replicate 3 times faster than SARS-CoV-1; hence, it can release/shed more viruses from the host cells [54]. Whether this enhanced mobility and instability of SARS-CoV-2 E are contributing in higher viral release is further needed to be explored (Table 1, Fig. 4). Here, the SARS-CoV-1 E and SARS-CoV-1-E-HMA complex were run as control since HMA can inhibit the VP activities. The differences between RMSD and RMSF of the ligand-bound and ligand-free SARS-CoV-1 E indicated that these compounds interfered with the normal physiology of the viral protein. The same patterns were also observed for ligand-bound and ligand-free SARS-CoV-2 E proteins. The flexibility of the proteins was altered in cytoplasmic, non-cytoplasmic and transmembrane regions. These flexibilities are critical for viral physiology [43]. MD simulation revealed that this region would gain rigidity which strongly supports that the viral physiology will be hindered extremely [55]. Hence, these deviations and alterations of the protein E strongly suggest that these amiloride analogs will disrupt the cation-selective IC activities.

Amiloride and HMA are well-studied compounds; therefore, in the near future, their antiviral activity against SARS-CoV-2 can be evaluated to develop new treatments. However, amiloride has some rare adverse effects and side effects. The most dangerous effects include hyperkalaemia [56]. Therefore, similar to nafamostat mesylate, serum potassium values should be monitored carefully in COVID-19 patients after the administration of amiloride analogs [57]. Although HMA has a lower K+ sparing diuretic effect than amiloride, these drugs might show side effects by hindering the general physiology of uPA [27,28].

Several amiloride analogs can inhibit the functions of coronavirus VPs. Our study strongly suggests their antiviral activities against SARS-CoV-2. Further in vitro screening and in vivo experiments are necessary to consider amiloride analogs as a prospective drug against this virus.

**ORCID**

Abdullah All Jaber: https://orcid.org/0000-0001-8964-7350
Zeshan Mahmud Chowdhury: https://orcid.org/0000-0002-6263-4960
Arittra Bhattacharjee: https://orcid.org/0000-0001-6019-3797

**Authors’ Contribution**

Conceptualization: AAJ, ZMC, AB, MM. Formal analysis: AAJ, ZMC, AB, MM. Methodology: AAJ, ZMC, AB, MM. Writing - original draft: AAJ, ZMC, AB. Writing - review & editing: AB, MM, CAK, ZAB.

**Conflicts of Interest**

No potential conflict of interest relevant to this article was reported.
Acknowledgments

The authors are grateful to Reactome Icon Library and GalaxyHomomer. These websites helped to generate the figures during the study.

Supplementary Materials

Supplementary data can be found with this article online at http://www.genominfo.org.

References

1. Keni R, Alexander A, Nayak PG, Mudgal J, Nandakumar K. COVID-19: emergence, spread, possible treatments, and global burden. Front Public Health 2020;8:216.

2. Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 2005;102:14040-14045.

3. Debink K, Agnihotram S, Gralinski LE, Plante JA, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med 2015;21:1508-1513.

4. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-1820.

5. Zhu Z, Lian X, Su X, Wu W, Marraro GA, Zeng Y. From SARS to MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res 2020;21:224.

6. Castano-Rodriguez C, Honrubia JM, Gutierrez-Alvarez J, DeDiego ML, Nieto-Torres JL, Jimenez-Guardeno JM, et al. Role of severe acute respiratory syndrome coronavirus E protein ion channels and 8a in replication and pathogenesis. mBio 2018;9:e02325-17.

7. Ewart GD, Sutherland T, Gage PW, Cox GB. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol 1992;69:517-528.

8. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992;69:517-528.

9. Pavlovic D, Neville DC, Argaud O, Blumberg B, Dwarka RA, Fischer WB, et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A 2003;100:6104-6108.

10. Hyser JM, Collinson-Pautz MR, Utama B, Estes MK. Rotavirus disrupts calcium homeostasis by NSP4 viroporin activity. mBio 2010;1:e00265-10.

11. Hover S, Foster B, Barr JJ, Mankouri J. Viral dependence on cellular ion channels: an emerging anti-viral target? J Gen Virol 2017;98:345-351.

12. Verdia-Baguena C, Nieto-Torres JL, Alcaraz A, DeDiego ML, Torres J, Aguillera VM, et al. Coronavirus E protein forms ion channels with functionally and structurally-involved membrane lipids. Virology 2012;432:485-494.

13. Nieto-Torres JL, Verdia-Baguena C, Jimenez-Guardeno JM, Regla-Nava JA, Castano-Rodriguez C, Fernandez-Delgado R, et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology 2015;485:330-339.

14. Shah A. Novel coronavirus-induced NLRP3 inflammasome activation: a potential drug target in the treatment of COVID-19. Front Immunol 2020;11:1021.

15. DeDiego ML, Nieto-Torres JL, Regla-Nava JA, Jimenez-Guardeno JM, Fernandez-Delgado R, Fett C, et al. Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol 2014;88:913-924.

16. Scott C, Kankanala J, Foster TL, Goldhill DH, Bao P, Simmons K, et al. Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza. PLoS Pathog 2020;16:e1008716.

17. Tong TR. Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle. Expert Opin Ther Pat 2009;19:415-431.

18. Pillaiyar T, Meenakshisundaram S, Manickam M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today 2020;25:668-688.

19. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536-544.

20. Li S, Yuan L, Dai G, Chen RA, Liu DX, Fung TS. Regulation of the ER stress response by the Ion channel activity of the infectious bronchitis coronavirus envelope protein modulates virion release, apoptosis, viral fitness, and pathogenesis. Front Microbiol 2019;10:3022.

21. Wilson L, Gage P, Ewart G. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology 2006;353:294-306.

22. Pervushin K, Tan E, Parthasarathy K, Lin X, Jiang FL, Yu D, et al. Structure and inhibition of the SARS coronavirus envelope protein ion channel. PLoS Pathog 2009;5:e1000511.

23. Silva LR, da Silva Santos-Junior PF, de Andrade Brandao J, Anderson L, Bassi EJ, Xavier de Araujo-Junior J, et al. Druggable tar-
gets from coronaviruses for designing new antiviral drugs. Bioorg Med Chem 2020;28:1157-45.

24. Bhattacharjee A, Hossain MU, Chowdhury ZM, Rahman SM, Bhuyan ZA, Salimullah M, et al. Insight of druggable cannabinoid against estrogen receptor beta in breast cancer. J Biomol Struct Dyn 2021;39:1688-1697.

25. Hossain MU, Bhattacharjee A, Emon MT, Chowdhury ZM, Mosaib MG, Mourin M, et al. Recognition of plausible therapeutic agents to combat COVID-19: an omics data based combined approach. Gene 2021;771:145368.

26. Lant AJ, Smith AJ, Wilson GM. Clinical evaluation of amiloride, a potassium-sparing diuretic. Clin Pharmacol Ther 1969;10:50-63.

27. Buckley BJ, Aboelela A, Minaei E, Jiang LX, Xu Z, Ali U, et al. 6-Substituted hexamethylene amiloride (HMA) derivatives as potent and selective inhibitors of the human urokinase plasminogen activator for use in cancer. J Med Chem 2018;61:8299-8320.

28. Matthews H, Ranson M, Tyndall JD, Kelso MJ. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA). Bioorg Med Chem Lett 2011;21:6760-6766.

29. Scott C, Griffin S. Viroporins: structure, function and potential as antiviral targets. J Gen Virol 2015;96:2000-2027.

30. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, et al. Protein identification and analysis tools on the ExPASy server. In: The Proteomics Protocols Handbook (Walker JM, ed.). Totowa: Humana Press, 2005. pp. 571-607.

31. El-Gebali S, Mistry J, Bateman A, Eddy SR, Luciani A, Potter SC, et al. The Pfam protein families database in 2019. Nucleic Acids Res 2019;47:D427-D432.

32. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 2001;305:567-580.

33. Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nuculeic Acids Res 2004;32:WS26-W531.

34. Bhattacharya D, Nowotny J, Cao R, Cheng J. 3Dredefine: an interactive web server for efficient protein structure refinement. Nucleic Acids Res 2016;44:W406-W409.

35. Ko J, Park H, Heo L, Seok C. GalaxyWEB server for protein structure prediction and refinement. Nucleic Acids Res 2012;40:W294-W297.

36. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 2018;46:W296-W303.

37. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7:42717.

38. Kim S, Thiessen PA, Bolten EE, Chen J, Fu G, Ginulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res 2016;44:D1202-D1213.

39. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455-461.

40. DeLano WL. Pymol: an open-source molecular graphics tool. Collaborative Computational Project No. 4, 2002. Accessed 2021 Oct 10. Available from: http://www.wwpymol.org/newsletter40/11_pymol.pdf.

41. Petterson EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera: a visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605-1612.

42. Casares D, Escriba PV, Rossello CA. Membrane Lipid Composition: effect on Membrane and Organelle Structure, Function and Compartmentalization and Therapeutic Avenues. Int J Mol Sci 2019;20.

43. Nieva JL, Madan V, Carrasco L. Viroporins: structure and biological functions. Nat Rev Microbiol 2012;10:563-574.

44. Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem 2008;29:1859-1865.

45. Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 2008;4:435-447.

46. Kutzner C, Pall S, Fechner M, Estermann A, de Groot BL, Grubmüller H. More bang for your buck: Improved use of GPU nodes for GROMACS 2018. J Comput Chem 2019;40:2418-2431.

47. V’Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 2021;19:155-170.

48. Rehman M, Tauseef I, Aalia B, Shah SH, Junaid M, Haleem KS. Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future. Future Virol 2020;15:471-482.

49. Wilson L, McKinlay C, Gage P, Ewart G. SARS coronavirus E protein formscation-selective ion channels. Virology 2004;330:322-331.

50. Parthasarathy K, Ng L, Lin X, Liu DX, Pervushin K, Gong X, et al. Structural flexibility of the pentameric SARS coronavirus envelope protein ion channel. Biophys J 2008;95:L39-L41.

51. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J 2019;16:699.
52. Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep 2020;19:100682.
53. Mourin M, Bhattacharjee A, Wai A, Hausner G, O’Neil J, Dibrov P. Pharmacophore-based screening and modification of amiloride analogs for targeting the NhaP-type cation-proton antiporter in Vibrio cholerae. Can J Microbiol 2021;67:835-849.
54. Chu H, Chan JF, Wang Y, Yuen TT, Chai Y, Hou Y, et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis 2020;71:1400-1409.
55. Salsbury FR Jr. Molecular dynamics simulations of protein dynamics and their relevance to drug discovery. Curr Opin Pharmacol 2010;10:738-744.
56. Sun Q, Sever P. Amiloride: a review. J Renin Angiotensin Aldosterone Syst 2020;21:1470320320975893.
57. Okajima M, Takahashi Y, Kaji T, Ogawa N, Mouri H. Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: four case reports. World J Clin Cases 2020;8:5320-5325.